Skip to main content
Elsevier

The Vaccine Book

New Insights, Approaches, and Technologies

  • 3rd Edition - February 1, 2027
  • Latest edition
  • Editors: Fabio Bagnoli, Rino Rappuoli, Sanjay Phogat
  • Language: English

The Vaccine Book: New Insights, Approaches and Technologies, Third Edition provides comprehensive information on the current and future world of vaccines. It reveals the scientifi… Read more

Description

The Vaccine Book: New Insights, Approaches and Technologies, Third Edition provides comprehensive information on the current and future world of vaccines. It reveals the scientific opportunities and potential impact of vaccines, including economic and ethical challenges, problems encountered when producing vaccines, how clinical vaccine trials are designed, and how to introduce vaccines into widespread use. Although vaccines are now available for many diseases, there are still challenges ahead for major diseases such as AIDS, tuberculosis, and malaria. Edited by a new, highly experienced team of editors, the 3rd edition provides new approaches, design, and vaccine platform tools to develop vaccines quicker.

This new edition is fully updated and designed for students, researchers, public health offcials, and all others interested in increasing their understanding of vaccines.

Key features

  • Includes new vaccines and current concepts as well as vaccine developments to prepare for new pandemics
  • Provides insights into diseases that could be prevented, along with the challenges facing research scientists in the world of vaccines
  • Delivers ideas about challenges facing public and private industrial investors in the vaccine area
  • Discusses the problem of declining immunization rates and vaccine hesitancy

Readership

Students, researchers, public health officials, and all others interested in increasing their understanding of vaccines Family Practitioners, Infectious Disease Specialists, Internists, Nurse Practitioners, Nurses, Pediatricians, Pharmacists, Physician Assistants, Physicians, Vaccine Program Administrators, and others involved in vaccine programs and vaccine delivery

Table of contents

Part I: Vaccines status quo

1. Currently available viral vaccines, their targets and technologies

2. Currently available bacterial & parasite vaccines, their targets and technologies

3. Immunology behind mechanism of action of vaccines

4. Adjuvants and their use in vaccines

5. Vaccine discovery approaches and tools

6. Vaccine development, regulatory path and launch in the market

7. Health economics of vaccines

8. COVID-19: a disaster and a revolution

Part II: New vaccines and technologies for addressing unmet medical needs   

9. Key vaccines still lacking globally and their potential impact (including AMR)

10. New approaches and tools for discovering vaccines

11. New technologies and tools for designing vaccines

12. New vaccine platforms technologies: mRNA, DNA, viral vectors, OMV, bioconjugates.

13. Technical, manufacturing, regulatory and development aspects of mRNA-based vaccines

14. Faster ways for developing vaccines

15. Getting ready to next pandemics

Product details

  • Edition: 3
  • Latest edition
  • Published: February 1, 2027
  • Language: English

About the editors

FB

Fabio Bagnoli

Fabio Bagnoli is Senior Director at GSK, Research & Development. He is Discovery Project Leader & Translation Science Leader. As Discovery Project Leader he drives several teams composed of experts in all areas of research & development with the aim of discovering and developing new vaccines and monoclonal antibodies. As Translational Science Leader he is driving clinical research studies, biomarkers identification, and human organotypic modelling. Research conducted by Fabio led to the development of various vaccine candidates as well as filing of various patents and publications on different human pathogens. He has served as editor of several publications and as coordinator of industrial-academic efforts.
Affiliations and expertise
Glaxo Smith Kline, Italy

RR

Rino Rappuoli

Rino Rappuoli is Senior Vice President, Head of Vaccine Research and Development at GSK. Previously, he served as visiting scientist at Rockefeller University and Harvard Medical School and held roles at Sclavo, Vaccine Research and CSO, Chiron Corporation, and Novartis Vaccines. He is Chief Scientist and Head External R&D, GSK Vaccines and has served as visiting scientist at Rockefeller University and Harvard Medical School. He is an elected member of the US National Academy of Sciences and the European Molecular Biology Organization. His awards include the Paul Ehrlich and Ludwig Darmstaedter Prize (1991), Italian President Gold Medal (2005), Albert Sabin Gold Medal (2009). In 2013 he was nominated third most influential person worldwide in the field of vaccines (Terrapin). In 2015 he was awarded Fellowship of Imperial College Faculty of Medicine London and the Maurice Hilleman Award.
Affiliations and expertise
Glaxo Smith Kline, Italy

SP

Sanjay Phogat

Sanjay Phogat is Vice President at GSK, Research & Development. He is the Discovery Performance Unit (DPU) head. As DPU head along with his team, he drives the discovery portfolio which includes bacterial, fungal vaccines, and monoclonal antibodies against infectious diseases. Sanjay is an infectious diseases expert with over twenty years of experience and a strong understanding of vaccine research and development. Sanjay’s unique experience covers a broad range of organizations varying from academia, government, not-for-profit, and pharma. He is scientific advisor for nonprofit organizations discovering antibodies for HIV and co-founder of Global Alliance of Indian biomedical professional and NIH visiting fellow committee. He has served as editor/co-editor/reviewer of several publications and has published over 80 scientific papers; many are highly cited and in very high impact journals.
Affiliations and expertise
President, GSK, Research and Development, Italy